Principal Financial Group Inc. Has $18.01 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Principal Financial Group Inc. decreased its position in Repligen Co. (NASDAQ:RGEN) by 30.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,991 shares of the biotechnology company’s stock after selling 52,435 shares during the quarter. Principal Financial Group Inc. owned 0.22% of Repligen worth $18,006,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Toronto Dominion Bank raised its position in Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares during the last quarter. MML Investors Services LLC lifted its position in shares of Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC boosted its holdings in Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 105 shares during the last quarter. Finally, CWM LLC grew its position in Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

NASDAQ RGEN opened at $145.78 on Friday. The stock has a market cap of $8.17 billion, a PE ratio of -393.99, a P/E/G ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a 50-day moving average of $144.45 and a 200-day moving average of $141.69. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period last year, the business posted $0.23 earnings per share. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Thursday, December 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $185.20.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.